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Background: Based upon the acquainted loss of dopaminergic neurons in the substantia nigra in Parkinson’s
disease (PD), we hypothesised changes in magnetic resonance imaging signal intensities of the basal ganglia to be
useful as an additional technical tool in the diagnostic work-up.
Methods: Region-of-interest analyses (substantia nigra and globus pallidus internus) of T2-weighted scans were
performed in seventy subjects with PD, 170 age- and gender-matched controls and 38 patients with an atypical
form of neurodegenerative Parkinsonian syndrome (N = 11 multisystem atrophy, N = 22 progressive supranuclear
palsy, N = 5 corticobasal syndrome).
Results: In patients with PD, significant changes in signal intensities within the substantia nigra were observed
compared to controls at p < 0.001. For the globus pallidus internus, signal alterations in PD and progressive
supranuclear palsy were found to be significant (p < 0.001) if compared to controls. Furthermore, signal changes of
substantia nigra correlated with signal intensities of globus pallidus internus in the ipsilateral hemisphere in both
groups. Sensitivity was 86% and specificity was 90% for the combined analysis of substantia nigra and globus
pallidus internus in the complete patient sample versus controls.
Conclusions: Signal alterations of substantia nigra and globus pallidus internus in routine magnetic resonance
imaging were useful to distinguish patients with PD from controls. In addition, signal changes in globus pallidus
internus could be used to differentiate progressive supranuclear palsy patients from controls. These analyses have
the potential to serve as an additional non-invasive technical tool to support the individual differential diagnosis
of PD.
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Morphological changesBackground
So far, the diagnosis of Parkinson’s disease (PD) is
mainly based on the presence of characteristic features
in a set of clinical assessments [1,2]. Nevertheless, about
32% of post mortem proven PD were not identified by
those criteria. Jankovic et al. found 65% of those cases who
had initially been diagnosed as PD to have an alternate
diagnosis after the 7.6-year follow-up [3], including multi-
system atrophy (MSA), progressive supranuclear palsy* Correspondence: jan.kassubek@uni-ulm.de
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reproduction in any medium, provided the or(PSP), Alzheimer’s disease (AD) as well as cerebrovascular
events, indicating that the clinically based diagnosis
provides limited accuracy [2,4]. Non-motor symptoms are
increasingly used for the clinical diagnosis, including hypos-
mia, sleep disturbances, behavioral/emotional dysfunction,
dysautonomia, depressive symptoms, and chronic pain [5].
However, since their sensitivity and specificity cannot be
determined yet, it would be beneficial to add further tech-
nical tools that might support the clinically suspected
diagnoses.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Overview of clinical data of all patient groups
N Age
(mean ± SD)
Hoehn & Yahr Duration of
disease in years
(mean ± SD)
PD 70 71 ± 9 stage 1: 2/70 9.0 ± 0
stage 2: 13/70 6.1 ± 4.8
stage 3: 22/70 5.0 ± 4.7
stage 4: 23/70 7.2 ± 5.3
stage 5: 10/70 7.6 ± 6.8
MSA 11 62 ± 6 - 2.4 ± 1.6
PSP 22 70 ± 8 - 3.0 ± 2.4
CBS 5 65 ± 4 - 2.3 ± 1.9
CON 170 66 ± 10 - -
Abbreviations: PD idiopathic Parkinson’s disease, MSA multiple system atrophy,
PSP progressive supranuclear palsy, CBS corticobasal syndrome, CON control
persons.
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computed tomography or positron emission tomogra-
phy represents a diagnostic tool which supports the
classification of Parkinsonian syndromes including their
early diagnosis in the clinical routine [6]. As a fully
non-invasive imaging tool, ultrasound sonography of the
substantia nigra (SN) can be used for the investigation
of regional hyperechogenicity, but requires an experi-
enced observer for the evaluation [7]. Conventional
magnetic resonance imaging (MRI), on the contrary, is
only used yet for exclusion of other underlying patholo-
gies, e.g. lesions of vascular origin or MRI findings
suspicious for atypical Parkinsonian forms [8]. Several
attempts were performed to explore PD-associated brain
alterations via MRI like diffusion tensor imaging, and
some of those studies revealed promising results with a
regional decrease in fractional anisotropy in the SN of
PD patients compared with control persons [9-12]. Un-
fortunately, those advanced MRI-based methods are not
applicable in routine diagnostic assessments yet as specific
data acquisition and time-consuming post-processing
procedures are still essential for evaluation of these
approaches.
Thus, we performed an MRI-based study in PD on
the basis of the following conceptual assumptions and
hypotheses: (i) signal alterations in MRI have to be
investigated in routine diagnostics to be easily available
and broadly applicable, (ii) we suspected signal changes
to be visible in SN as well as the corresponding globus
pallidus internus (GPI) [13], (iii) MRI signal intensities
of those regions should be able to differentiate at least
PD from control subjects (CON) and possibly from
atypical Parkinsonian syndroms in order to be useful
as an additional technical tool in the diagnostic
workup. Accordingly, we investigated whether or not
signal changes in MRI correlated with the clinical




The study was performed as a retrospective case-
controlled MRI data bank analysis. MRI data acquisition
in patients with Parkinsonian syndromes and controls
had been approved by the Ethics Committee of the Uni-
versity of Ulm, Germany, and patients and controls gave
informed consent to the scientific use of their anon-
ymised data sets. The study was in compliance with the
Helsinki Declaration. Seventy consecutive patients with
PD who had been clinically diagnosed by board-certified
neurologists on the basis of the UK Brain Bank criteria
for the diagnosis of PD [14,15] were included. For
patients’ ages and Hoehn and Yahr stages, please see
Table 1.The additional patient groups with an atypical form of
Parkinsonian syndrome comprised 11 subjects with MSA
(diagnosed according to [16]), 22 patients with progressive
supranuclear palsy (diagnosis was set according to [17]) as
well as 5 patients with corticobasal syndrome (diagnosed
according to [18]). As the control group, 170 patients with-
out any neurological sign of extrapyramidal motor symp-
toms were included, the most common diagnoses were
transitory ischemic attack (N = 35), dizziness (N = 31),
seizures (N = 20), headache (N = 13) and paralysis of the
seventh brain nerve (N = 10). All MRI data sets of the con-
trols were thoroughly checked for any structural brain
pathology by two independent experienced observers
(JK, AU). Additional clinical data for all patients and con-
trols are given in Table 1.
Data acquisition and post-processing
MRI scans were acquired on a 1.5 Tesla routine clinical
MRI scanner (SIEMENS MAGNETOM Symphony, a
TIM system, Erlangen, Germany) equipped with a stand-
ard 12 channel head coil. As elderly patients often show
microvascular lesions, exclusion criteria were used
according to [19], only allowing grade 0 or 1, the latter
only if not found in the basal ganglia, and the respective
data sets of patients with higher-grade vascular lesions
were not considered for statistical evaluation.
All patients and controls underwent the same clinical
routine MRI protocol, consisting of whole-brain cover-
ing sequences of diffusion-weighted imaging (DWI) in-
cluding apparent diffusion coefficient-maps (ADC), T1-,
T2-, T2*-weighted imaging as well as fluid-attenuated
inversion recovery (FLAIR). The sequence parameters
are given in the Additional file 1: Table S1. In the follow-
ing, we focused all analyses on T2-weighted image data,
all additionally acquired data sets were only used to rule
out further brain pathologies.
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All data analyses were performed by two independent
experienced observers. Calculation of test/retest (i.e.,
intra-rater) and inter-rater reliability was performed meas-
uring of the bilateral SN and GPI ROIs as well as ROIs in
the sinus and lateral cerebral ventricles in a subset of 55
patients, including PD and CON. Statistical evaluation
was performed according to Bland and Altman [20].
By use of a dedicated certified workstation (AGFA,
IMPAX > ES, DS 3000, Belgium), regions of interest
(ROI) in the SN as well as the GPI were manually traced
by the two specifically trained raters with a mouse
driven cursor using T2-weighted axial images. The raters
were blinded to the diagnosis. The T2-weighted images
allow for the identification of the SN pars reticulata as a
hypointense area in the posterior region of the crus cere-
bri, while a relative hyperintense area between the SN
pars reticulata and the red nucleus represents the pars
compacta [21,22]. The ROI had the same size in each
patient, independent of the existence of hyperintense
signal alterations in the SN or the GPI. The ROI size
was approximately 2.5 cm × 0.5 cm for SN and 1.5 cm ×
0.25 cm for GPI, variability was approximately ± 0.2 cm.
T2- weighted imaging provides images with an intensity
given in arbitrary units (a.u.) that depends on imaging
parameters and calibration parameters of the scanner in
addition to internal properties of the tissue. Therefore, a
normalisation algorithm was used in which the original
histogram of the whole image intensity distribution was
stretched and shifted according to defined image inten-
sities [23]:
I 0 x; yð Þ ¼ IM  IL
Imax  Imin I x; yð Þ  Iminð Þ þ IL ð1Þ
In Equation 1, I(x,y) denotes the original image intensity
(averaged in the respective ROI) and Imax and Imin denote
normalization intensities which were evaluated from ROIs
(positioned in the respective slices) in the cerebrospinal
fluid (hyperintense) and in the sinuses (hypointense), re-
spectively. The re-normalized intensity I’(x,y) is obtained
by re-scaling to IM and IL which represent the arithmetic
average of intensities of the cerebrospinal fluid (IM) and
the sinus (IL), respectively, of all data sets. It should be
noted that IM and IL define a new intensity histogram
whose characteristics can be freely chosen. In the follow-
ing, the re-normalized intensity I’(x,y) is denoted as
intensity.
Correlation analysis
We performed correlation analyses of the signal inten-
sities of the SN and the corresponding signal intensities
in the GPI of the same side. Since we were interested ifthe extent of the signal alterations in the SN and the
GPI depended on the duration of the disease, these cor-
relation analyses were also performed. In a final step, we
compared the MRI findings with clinical symptoms in
the PD group to address the question if MRI signal
intensities of SN have the potential to predict the clini-
cally dominant affected side and vice versa. A step by
step explanation of the analysis procedure is given in the
Additional file 2: Table S2.
Statistics
All statistical analyses were performed using the soft-
ware SigmaStat 3.5 (Systat Software Inc., Chicago, USA).
The comparison of signal intensities between the differ-
ent groups was based on calculations using ANOVA
Kruskal Wallis, correlations were calculated by Pearson’s
correlation coefficient for comparison of SN and GPI in
the same hemisphere. Correlations of signal alterations
in SN and GPI with duration of the disease as well as
Hoehn & Yahr stages were performed using Spearman
correlation. The analyses of test/retest (intra-rater) and
inter-rater reliability were performed according to the
method by Bland and Altman [20]. In addition, Pearson’s
correlation for intra- and inter-rater analysis results was
calculated. Statistical significance was set at p < 0.05.
In order to estimate the predictive power of the tech-
nique, a threshold for discrimination of signal hyperin-
tensities between the complete patient sample and the
control sample was defined. For this purpose, we sum-
marised the complete patient sample including all inves-
tigated pathologies, since the low sample sizes of the
Parkinsonian syndromes other than PD did not allow for
separate analysis. Then, left and right SN values were
arithmetically averaged (averaged SN intensity, ASN),
the same was performed for left and right GPI values
(averaged GPI intensity, AGPI). The threshold for the in-
tensity value for SN was defined as the average value of
all ASN of the controls + standard deviation of the con-
trols0 ASN values, resulting in a threshold value for ASN
(THSN) = 380 arbitrary units (a.u.). In the corresponding
way, a threshold for GPI was defined as THGPI = 310
a.u.. Then, pathology was defined in three ways: abnor-
mality for SN (ASN > THSN), abnormality for GPI
(AGPI > THGPI), and also a combination, i.e. either ASN
or AGPI was higher than the respective threshold (ASN
> THSN or AGPI > THSN). The leave one out method
was performed to calculate the predicted residual error
sum of squares (PRESS).
Results
Signal intensities of SN and GPI
ROI analyses of the signal intensities of SN and GPI of
both sides were performed in the same way for all
patients and controls. An example for the ROI-based
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Figure 1. In PD patients, we observed hyperintense
alterations of the SN, and the comparisons of the cor-
rected signal intensities between PD and CON were
significant for the SN in both hemispheres at p < 0.001.
In addition, we also observed PD-associated hyperin-
tense signal alterations of the GPI in both hemispheres.
To a lesser degree, hyperintense signal alterations of the
GPI were observed in PSP patients compared to con-
trols. The statistical comparison of the GPI signal inten-
sities between PD as well as PSP and CON was also
significant at p < 0.001. The results of the data analysis
are summarised in Figure 2. No significant differences
could be found for MSA and CBS compared with CON
for either GPI and SN in both hemispheres.
Comparison of signal intensities of SN and the ipsilateral
GPI
Correlation analyses of the altered signal intensities of
the SN and the corresponding signal intensities in the
ipsilateral GPI revealed statistically significant correla-
tions for PD as well as for PSP and CON with p < 0.05.
Data are depicted in Figure 3.
Test/retest (intra-rater) and inter-rater reliability
Here, the scatter of differences of single pair-values was
compared. In the case of a symmetrical distribution ofFigure 1 Illustration of ROI definition in the SN and the GPI. On
the left side, whole brain image at the location of the SN and the
magnification of the midbrain with the hyperintense signal of SN
are depicted and marked by an arrow. On the right, whole brain
image at the location of the GPI and the magnification of the basal
ganglia with the hyperintense signal of the dorsomedial GPI are
illustrated. Abbreviations: SN = substantia nigra, GPI = globus pallidus
internus.differences, 95% of the values are located in the range of
δ ± 2σ (δ, bias; σ, standard deviation). This limit of ac-
cordance is represented as dashed lines in Figure 4. For
test/retest reliability (intra-rater reliability), 94 % of tests
were within the 2σ range representing an acceptable re-
producibility of the test procedure. Also for inter-rater
reliability (two raters), 96% of tests were within the 2σ
range, indicating a good reproducibility of data analysis.
Correlations for intra-rater variability and inter-rater
variability were 0.97 (p < 0.0001) and 0.62 (p < 0.0001),
respectively.
Comparison of signal intensities in SN and GPI with
duration of the disease and H&Y stages
Correlation analyses of the extent of signal alterations in
the SN and the GPI and the duration of the disease
showed no significant changes (p > 0.05); as a limiting
factor, duration of the disease could not be determined
retrospectively for 9 out of 70 PD patients. The compari-
son of alterations in both anatomical areas with Hoehn
& Yahr stages showed a significant positive correlation
at p < 0.03.
Comparison of clinical symptoms with the MRI data
Here, positive predictive values, analysed separately for
both sides, were not promising as their levels were in
random distribution (positive predictive value (PPV) for
the left side of SN ([17/(17 + 15)] = 0.53; PPV for the
right side of SN [13/(13 + 12)] = 0.52).
Calculation of sensitivity, specificity, positive predictive
value, and negative predictive value
Statistical measures (sensitivity, specificity, PPV, NPV as
well as statistical data of the leave one out method) are
given in Table 2. In summary, the thresholds calculated
as described above (380 a.u. for SN and 310 a.u. for GPI,
respectively) showed a high sensitivity (86%) and NPV
(90%) for the combination of SN and GPI analysis in the
complete patient sample versus controls. Specificity and
PPV were similar for SN and GPI investigations, while
sensitivity and NPV were lower for SN than for GPI.
Discussion
Since PD diagnosis is still mainly set on clinical assessments
based upon the presence of characteristic features, an add-
itional technical tool to support the clinically suspected
diagnosis would be beneficial. Unfortunately, broadly avail-
able non-invasive neuroimaging tools are limited mainly to
transcranial sonography which crucially depends on the
rater’s expertise, whereas MRI is primarily performed to ex-
clude other underlying pathologies.
For these reasons, we investigated MRI signal inten-
sities of SN and GPI in a clinical routine setting using a
clinical 1.5T MRI scanner with a standard protocol for
Figure 2 Signal intensities of the substantia nigra (SN) and the globus pallidus internus (GPI) in the different groups given in arbitrary
units (a.u.). Plot shows 10th, 25th, 50th, 75th, and 90th percentiles and outliers. A: Signal intensities of the right SN. B: Signal intensities of the
left SN. C: Signal intensities of the right GPI. D: Signal intensities of the left GPI. The comparison between PD and CON was significant for SN on
both sides at p < 0.001. For the GPI on both sides, the statistical comparison between PD and CON as well as between PSP and CON showed
differences at p < 0.001. Abbreviations: PD = Parkinson’s disease, MSA =multisystem atrophy, PSP = progressive supranuclear palsy,
CBS = corticobasal syndrome, CON = control persons.
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observed T2-hyperintense signal changes of both the SN
and the GPI areas to be useful to support the diagnosis
of PD, whereas controls did not show these features.
Additionally, signal intensities of SN correlated with the
GPI area of the same side. In addition to these observa-
tions in PD and consistent with previous MRI-based
studies in atypical Parkinsonian syndromes, signal
changes in GPI were confirmed which can also be po-
tentially used to differentiate PSP patients from controls
[24]. In order to serve as an additional technical tool in
the diagnosis of PSP, these data have to be reproduced
and validated using a dedicated study design with inves-
tigation of larger numbers of PSP patients.
The thresholds (using the “or” combination) allowed
for a high sensitivity (86%) and NPV (90%) for the sam-
ple of all investigated pathologies. (Although MSA and
CBS showed no significant differences in the comparisonwith the control group, most probably due to the low
sample size, the complete patient group was compared
with controls in order to encompass all investigated dif-
ferential diagnoses.) Specificity and PPV were similar for
SN and GPI investigations, while sensitivity and NPV
were lower for SN than for GPI. The combined analysis
showed similar statistical values for sensitivity and NPV
as GPI alone. Taken together, we suggest the use of a
combination of GPI and SN in order to consider supple-
mentary information of SN rather than investigating GPI
alone.
Our results are in general agreement with previous
studies focusing on conventional MRI-based techniques
in the diagnosis and differential diagnosis of PD, which
revealed a broad spectrum of signal alterations in T1-,
T2- or T2*-weighted imaging within the SN [8,25]. In
contrast to most previous studies, however, we did not
investigate iron or hemosiderin depletion within the SN,
Figure 3 Correlations of signal intensity (SI) (in arbitrary units a.u.) of substantia nigra with globus pallidus internus on the same side
for all groups. Pearson correlation coefficient was significant for PD, PSP and CON with p < 0.05. Abbreviations: SN = substantia nigra,
GPI = globus pallidus internus, for the other abbreviations see Figure 2.
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ing in selective shortening of these relaxation times, but
rather T2-hyperintensities as a correlate of selective and
focal gliosis illustrating the upmost relevant neurodegen-
erative component of PD. In this context, our results
partly reflect the well-known neuroanatomical projec-
tional system of dopaminergic neurons of the SN to the
GPI without the necessity of advanced imaging techni-
ques such as tractography [26]. Beyond that, the pre-
sented altered signal intensities within the ROIs in theFigure 4 Test/retest and interrater reliability according to Bland-Altm
intervall (δ ± 2σ, σ - standard deviation – dashed line, limit of accorda
accordance. B: inter-rater reliability of 96% is within the limit of accordance
the test difference in a.u.deep brain structures were derived on an individual basis
without the need for any post-processing procedures.
What may be the pathophysiological correlate of the
signal alterations observed in the SN and GPI of our PD
patients? According to Braak et al., pathophysiological
processes of PD can be divided into six stages each of
which is marked by the continuous development of dis-
tinctive inclusion Lewy-bodies and evolves sequentially
with the beginning at definite predisposed vulnerable sites,
advancing from there in a predictable form through thean. Horizontal lines indicate δ (bias – straight line) and the 2σ
nce). A: test/retest (intra-rater) reliability of 94% is within the limit of
. SI (ROI) is the average signal intensity within a ROI in a.u., ΔSI (ROI) is
Table 2 Statistical calculation of sensitivity, specificity,
positive predictive value, and negative predictive value
(including leave one out method)
Sensitivity Specificity PPV NPV
ASN > THSN 0.72 ± 0.08 0.82 ± 0.02 0.72 ± 0.04 0.82 ± 0.06
AGPI > THGPI 0.84 ± 0.06 0.80 ± 0.03 0.73 ± 0.04 0.89 ± 0.04
Combination 0.86 ± 0.04 0.77 ± 0.05 0.70 ± 0.06 0.90 ± 0.04
Table 2 Statistical measures for defined thresholds: average substantia nigra
(ASN) value above threshold (THSN), average globus pallidus internus (AGPI)
above threshold (THGPI), and the combination, i.e. ASN > THSN or AGPI >
THGPI. Predicted residual error sum of squares (PRESS) values were calculated
by the leave one out method. Results are presented as statistical measure ±
PRESS. PPV positive predictive value, NPV negative predictive value.
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the disease can clinically be divided into a premotor
(stages 1–3) and a symptomatic phase (stages 4–6), while
the SN and the basal ganglia are pathophysiologically not
impaired in the premotor stages. In short, in Braak stage
3, the continuous, self-propagating process reaches the
mid- and forebrain including the pars compacta of the SN,
followed by the anteromedial temporal mesocortex, the
basal ganglia, the limbic system as well as the prefrontal
cortex in stage 4 while in the last two stages, pathoanato-
mical involvement includes the association areas of the
neocortex [1,13,28-31]. On the basis of this knowledge,
hyperintensities of SN and GPI, as observed in our MRI
data, may be a morphological sign of neurodegenerative
processes in the SN with consecutive degeneration of pro-
jection fibers to the corresponding GPI. This assumption
may also be strengthened by recent reports on stage-
dependent SN signal reduction as a putative marker of
neuromelanin loss in PD patients in high-resolution T1-
weighted imaging with magnetization transfer effect at 3
Tesla [32]. As an alternative theory, one could postulate
local magnetic field disturbances as a correlate of iron ac-
cumulation in the SN, but we do not favour this hypoth-
esis since T2*-weighted images did not show any
substantial signal alterations of the SN in our sample that
should be the case in iron deposition (data not shown).
However, this lack of evidence for iron deposit might not
only be a bias effect in our patient sample, but could also
be related to the applied T2*-sequence parameters and
also the field strength of our scanner. Here, recent studies
report a traceable increase in susceptibility of the pars
compacta in PD patients compared with controls by use
of susceptibility mapping at ultrahigh field (7 Tesla) and
advanced post processing methods [33].
There are some additional limitations to the interpret-
ation of these results. The major limitation is the appli-
cation of the MRI data analysis to a sample of clinically
diagnosed patients in a retrospective design. However,
due to the explorative approach of this pilot study, the
design with inclusion of clinically diagnosed patients in
different (including advanced) clinical stages was chosen.Due to its design, the study cannot overcome the chal-
lenge of missed PD diagnosis since it aimed to provide
imaging markers for identification of PD patients using
clinical assessment as the gold standard rather than
pathology. In the future, in order to test the value for
early PD diagnosis or differential diagnostics, a prospect-
ive design in early affected patients or cases of clinical
doubt or a retrospective design comprising patients with
neuropathologically proven PD diagnosis has to be used.
In addition, it has to be considered that a possible short-
coming may be the use of the 1.5T MRI scanner which
implies a limited local resolution in comparison to
higher field strengths although a 12-channel head coil
was applied. With respect to data analysis, computerised
analysis is necessary instead of pure visual inspection -
however, the ROI-based processing can be performed
within a few minutes on a standard workstation and
does not require any advanced qualification beyond
neuroanatomical identification of the basal ganglia struc-
tures. In addition, the thresholds used for the calculation
of sensitivity and specificity were defined ex post.
In summary, although the demonstrated results are
based on clinically diagnosed patients and therefore might
include a selection bias, our MRI-based findings seem to
have the potential to serve as an additional non-invasive
neuroimaging-based technical tool within the diagnostic
work-up for individual diagnosis of PD. Future studies
should set focus on the potential of this ROI-based MRI
analysis in early PD patients and might include further
technical assessments of the patients such as other im-
aging modalities including dopamine transporter (DaT)
scan. Furthermore, future studies might address the item
of the comparison of different computerised MRI-based
techniques in the imaging assessment of Parkinsonian syn-
dromes including susceptibility mapping and the analysis
of mean diffusivity values in DWI data.
Conclusions
Addressing the hypothesis-driven rationale of the study,
it can be concluded: In PD patients, we suspected signal
changes in MRI to be visible in SN as well as the corre-
sponding GPI. This could be confirmed as we found sig-
nal alterations in the above mentioned areas in PD
patients. Furthermore, MRI signal intensities of those
regions should be able to differentiate at least PD from
control subjects and possibly from atypical Parkinsonian
syndroms in order to be useful as a technical approach
to support clinical diagnostic aspects. The examination
should serve as an additional diagnostic-supporting tool
that could be easily available and broadly applicable
using standard routine MRI. This requirement was met
using a standard protocol for acquisition and a simple
ROI-based post-processing which can be performed
within few minutes.
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